Pharmacologic differences among the SSRIs: Focus on monoamine transporters and the HPA axis

CNS Spectrums

Volumn 9, Issue 6 SUPPL. 4, 2004, Pages 23-31

  Nemeroff, Charles B ^a   Owens, Michael J ^a  

^a Woodruff Memorial Building ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DESVENLAFAXINE; FLUOXETINE; FLUVOXAMINE; HYDROXYNEFAZODONE; NEFAZODONE; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MONOAMINE RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONIN UPTAKE; SIDE EFFECT;

EID: 3042698002     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025475     Document Type: Conference Paper

References (41)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Robins LN, Wing J, Wittchen H-U, et al. The Composite International Diagnostic Interview. Arch Gen Psychiatry. 1988;45:1069-1077.
4. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1997.
5. Kendler KS. Anna-Monika-Prize paper. Major depression and the environment: a psychiatric genetic perspective. Pharmacopsychiatry. 1998;31(1):5-9.
6. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-1562.
7. Abkevich V, Camp NJ, Hensel CH, et al. Predisposition locus for major depression at chromosome 12q22-12q23.2. Am J Hum Genet. 2003;73(6):1271-1281.
8. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of cortiocotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160(1):1-12.
9. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry. 1999;46:1219-1233.
10. Nestler EJ, Barrot, M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13-25.
11. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61:7-11.
12. Gutman DA, Nemeroff CB. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiot Behav. 2003;79(3):471-478.
13. Mullen PE, Martin JL, Anderson JC, Romans SE, Herbison GP. The long-term impact of the physical, emotional, and sexual abuse of children: a community study. Child Abuse Negl. 1996;20(1):7-21.
14. Saunders B, Villoponteaux L, Lipovsky J. Child sexual assault as a risk factor for mental disorders among women: a community survey. J Interpers Violence. 1992;7:189-204.
15. Ruppenthal GC, Arling GL, Harlow HF, Sackett GP, Suomi SJ. A 10-Year perspecitve of motherless-mother monkey behavior. J Abnorm Psychol. 1976;85(4):341-349.
16. Levine S, Wiener SG, Coe CL. Temporal and social factors influencing behavioral and hormonal responses to separation in mother and infant squirrel monkeys. Psychoneuroendocrinology. 1993;18(4):297-306.
17. Levine S. Infantile Experience and resistance to physiological stress. Science. 1975;126:405-406.
18. Newport DJ, Stowe ZN, Nemeroff CB. Parental depression: animal models of an adverse life event. Am J Psychiatry. 2002;159:1265-1283.
19. Vythilingam M, Heim C, Newport DJ, et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry. 2002;159(12):2072-2080.
20. Hammen C, Davila J, Brown G, Ellicott A, Gitlin M. Psychiatric history and stress: predictors of severity of unipolar depression. J Abnormal Psychol. 1992;101(1):45-52.
21. Kendler Ks, Kessler RC, Walters EE, et al. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry. 1995;152(6):833-842.
22. Schildkraut JJ. The catechotamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509-522.
23. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacologic profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249-258.
24. Kaplan H, Sadock BJ. Synopsis of Psychiatry: Behavioral Sciences, Clinical Psychiatry. 6th ed, rev. Hagerstown, MD: Lippincott, Williams, and Wilkins; 1991.
25. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry. 2003;64(Suppl 2):3-7.
26. Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry. 1992;49:817-823.
27. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord. 1997;45:5-18.
28. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305-1322.
29. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59:5-14.
30. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002;163(1):102-105.
31. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54(8):800-805.
32. Seeman P. Receptor Tables Vol.2: Drug Dissociation Constants for Neuroreceptors and Transporters. Schizophrenia Research: Toronto, Canada; 1993.
33. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161(96):826-835.
34. Owens MJ, Knight DL, Nemeroff CB. Paroxetine binding to the rat norephinephrine transporter in vivo. Biol Psychiatry. 2000;47:842-845.
35. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159(10):1702-1710.
36. Meyer JH, Wilson AA, Ginovaret N, et al. Occupancy of serotonin transporters by paroxetine and citaloptam during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843-1849.
37. Watkins L, Davidson JRT, Connor KM, et al. Effects of paroxetine and venlafaxine-XR on heart rate variability in depression. Poster presented at: 16th Annual Meeting of the European College of Neuropsychopharmacology; September 20-24, 2003; Prague, Czech Republic.
38. Carney RM, Blumenthal JA, Catallier D, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol. 2004;92(11):1277-1281.
39. Buckley NA, McManus PR. Fatal Toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325:1332-1333.
40. Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Plotsky PM. Long-term adaptations in glucoorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothatamo-pituitary-adrenal axis following neonatal maternal separation. Biol Psychiatry. 2004;55(4):367-375.
41. Holsboer F. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. Raven Press, Ltd: New York, NY:957-999.